Digestive health supplement lifts Immuron’s sales

By Meagan Evans. Published at Apr 15, 2019, in Biotech

Immuron Limited (ASX:IMC | NASDAQ:IMRN) today announced that sales for its commercially available products, including Travelan®, surged by 66% in the third quarter.

Immuron is an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the treatment of gut mediated diseases, including Travelan®, its over-the-counter gastrointestinal and digestive health supplement.

Worldwide product sales reached $616,000 in the quarter ending March 31, up from 371,000 in Q3 2018. While sales for the year to date hit $1.7 million, up 23% from this time a year ago.

In Australia, Travelan® sales rocketed to A$332,000 in Q3 FY19, representing a 73% increase over Q3 FY18 (A$192,000) demonstrating that efforts to raise consumer awareness of the brand through expanded co-operative Marketing initiatives with major Pharmacy banners have impacted positively on sales.

Sales for the year to March 31 of Travelan® in Australia exceeded the A$1 million mark and are 18% higher than the same time last year.

In the US, Travelan® sales surged ahead growing 60% YoY to A$266,000 for Q3 2019 as the partnership with USA’s largest travel medicine network, Passport Health continues.

Sales of Travelan® on the Amazon Platform are also steadily increasing. YTD March 31 US Sales (A$635,000) are sitting 27% higher than the same time last year.

Dr Gary S. Jacob, CEO of Immuron, said of the results, “Our concerted focus on expanding sales growth of Travelan® within existing markets, coupled with our re-entry into Canada puts us in a strong position for continued growth.

“We will continue to work towards expanded sales growth, with particular emphasis on building the market for Travelan® in North America.”

Today’s announcement follows news last week that IMC plans to pursue clinical development of IMM-124E, its bovine polyclonal antibody drug candidate to prevent travelers’ diarrhea, through a formal FDA registration pathway.

It also comes after the company's Chemist Warehouse Ad went live on April 12 and wil run through to April 18:

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Thanks for subscribing!